Track MedSmart Group's EBIT ($-220K) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2022
Trailing 12 months ending Sep 30, 2022
The latest EBIT for MSGP is $-220K as of September 2022. That compares with $-140K in the prior-year period — down 57.1% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside MedSmart Group's historical trend and sector peers before judging valuation or financial health.
Over the past year, MSGP's EBIT moved from $-140K to $-220K — a 57.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MedSmart Group's operating scale or balance-sheet position.
Against its sector companies, MSGP currently prints $-220K for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at MedSmart Group's growth, margins, and balance sheet.
A EBIT figure of $-220K for MSGP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.
After noting MSGP's EBIT ($-220K), review year-over-year change from $-140K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.